Condition: Ileal Pouch · Sponsor: Exegi Pharma, LLC
The aim of this study is to assess the safety and preliminary efficacy of treatment with EXE-346, a live biotherapeutic, which may reduce bowel movement frequency in patients with an ileal pouch-anal anastomosis (IPAA) and lead to a higher quality of life.
This description comes directly from the study's public registry record.
Emmes Project Management · 301-251-1161 · PROF_Study@emmes.com
Always discuss trial participation with your own doctor first.
| Cedars-Sinai Medical Center | Los Angeles, California, United States | Recruiting |
| Mayo Clinic - Florida (Inflammatory Bowel Disease Center) | Jacksonville, Florida, United States | Recruiting |
| Corewell Health | Grand Rapids, Michigan, United States | Recruiting |
| Mayo Clinic Department of Gastroenterology | Rochester, Minnesota, United States | Recruiting |
| Washington University School of Medicine | St Louis, Missouri, United States | Recruiting |
| NYU Langone Health | New York, New York, United States | Recruiting |
| University of North Carolina at Chapel Hill | Chapel Hill, North Carolina, United States | Recruiting |
| Penn State Health (Milton S. Hershey Medical Center) | Hershey, Pennsylvania, United States | Recruiting |
Get one email when the public record changes — results posted, or the study's status changes. Nothing else, ever.
We email about this public record only. Unsubscribe anytime with one click. Never medical advice.
This page is independently generated by Eichor from the public ClinicalTrials.gov record and re-synced daily. It is not the sponsor's official website unless claimed. Nothing here is medical advice; eligibility is always determined by the study team — talk to your own doctor first.
Source record: clinicaltrials.gov/study/NCT05938465